Tesetaxel: Additional Phase IIb data

Additional data from 44 evaluable patients in an open-label, U.S. Phase IIb trial showed that tesetaxel produced 1 complete response and 19 partial responses. The DCR was 82%. Furthermore, tesetaxel produced a response in 49% of patients with estrogen receptor-positive disease (n=35), with a median PFS of 7.3 months. In women with triple-negative breast cancer (TNBC; n=9), tesetaxel produced 3 responses. The most common >=grade 3 adverse event was neutropenia. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...